Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed to Accrual

IND.189 -- A phase II study of Interleukin-21 (rIL-21) in patients with metastatic or recurrent malignant melanoma -- was officially closed to accrual on August 17, 2009.

http://www.ctg.queensu.ca/trials/ind/i189/189.html